Zalatnai Attila, Galambos Eszter, Perjési Eszter
First Department of Pathology and Experimental Cancer Research, Semmelweis University, Faculty of Medicine, H-1085 Üllői út 26, Budapest, Hungary.
Pathol Oncol Res. 2019 Apr;25(2):521-525. doi: 10.1007/s12253-018-0426-4. Epub 2018 Jun 3.
The long-acting somatostatin analogs represent important weapons in treatment protocols of patients with neuroendocrine tumors. Because these peptides preferentially bind to the specific somatostatin receptors, the targeted therapy requires detection of them. As one of the national consulting centers, here we present the results of the immunohistochemically positive neuroendocrine neoplasms diagnosed between 2010 and 2014. Twenty-four paraffin-embedded cases (14 females 10 men, 21-79 years) from different localizations were found to express somatostatin-receptor type 2 (SSTR2). None of the patients has received previous hormonal therapy. The immune reactions have shown membranous, cytoplasmic or mixed patterns. There was no correlation between the expression and the chromogranin A levels, the grades or the hormonal activity/inactivity of the given neoplasms. Our results show that the immunohistochemical detection of SSTR2 is a quick, reliable and effective tool that provides useful information to the oncologists for the therapeutic decision. Because the incidence of the neuroendocrine tumors is still low, centralized pathological units are needed to perform such technique.
长效生长抑素类似物是神经内分泌肿瘤患者治疗方案中的重要武器。由于这些肽优先结合特定的生长抑素受体，因此靶向治疗需要检测这些受体。作为国家咨询中心之一，我们在此展示2010年至2014年间免疫组化呈阳性的神经内分泌肿瘤的诊断结果。发现来自不同部位的24例石蜡包埋病例（14名女性，10名男性，年龄21 - 79岁）表达2型生长抑素受体（SSTR2）。所有患者此前均未接受过激素治疗。免疫反应呈现膜性、胞质性或混合性模式。给定肿瘤的SSTR2表达与嗜铬粒蛋白A水平、分级或激素活性/无活性之间无相关性。我们的结果表明，SSTR2的免疫组化检测是一种快速、可靠且有效的工具，可为肿瘤学家提供有用信息以用于治疗决策。由于神经内分泌肿瘤的发病率仍然较低，需要集中的病理单位来开展此项技术。
